

ASX Release

Date: 4 September 2024

**Section 708A(5)(e) disclosure notice – Issue of Ordinary Shares**

Imugene Limited (ASX: IMU) (**Imugene** or **Company**) has issued 87,999,186 fully paid ordinary shares as part settlement of deferred consideration for the Licence Agreement with Precision Biosciences Inc., entered into and announced on 16 August 2023 as per the Appendix 2A released today.

**Details of the securities issued are as follows:**

Class of securities:	Ordinary shares
ASX Code of the securities:	IMU
Date of the issue or expected issue of the securities:	3 September 2024
Total number of securities issued or expected to be issued:	87,999,186

The Company gives notice pursuant to section 708A(5)(e) of the *Corporations Act 2001* Cth (**Corporations Act**) that:

1. the above securities have been issued without disclosure to investors under part 6D.2 Corporations Act;
2. this notice is given under section 708A(5)(e) of the Corporations Act and in accordance with section 708A(6) of the Corporations Act;
3. at the date of this notice, the Company has complied with:
  - a. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - b. sections 674 and 674A of the Corporations Act; and
4. at the date of this notice, there is no information required to be disclosed by the Company which is 'excluded information' (as defined in sections 708A(7) and 708A(8) of the Corporations Act).



## Enquiries

For more information please contact:

Leslie Chong  
Managing Director and Chief Executive Officer  
T: +61 458 040 433  
info@imugene.com

Follow us on Twitter and Instagram @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer, multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

*Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.*